In one paragraphArticle in Journal of human hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Joshua A JacobsDepartment of Internal Medicine, Division of Cardiovascular Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA.
Jordan B KingIntermountain Healthcare Department of Population Health Sciences, Divisions of Health System Innovation and Research and Biostatistics, Spencer Fox-Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-6783-7951 Adam P BressIntermountain Healthcare Department of Population Health Sciences, Divisions of Health System Innovation and Research and Biostatistics, Spencer Fox-Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-2259-5039 Jaejin AnDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Kelsey B BryantDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Funding
Continuation of the Coordinating Center for the Chronic Renal Insufficiency Cohort (CRIC) StudyU24DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Amanda Hyre Anderson, Laura M Dember · 2018 to 2026
$21.5MTargeting Skeletal Muscle Perfusion and Oxidative Capacity in HFpEFR01HL155599 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ZAMANI, PAYMAN · 2021 to 2025
$3.9MCardiovascular Risk, Vascular and Kidney Damage in COVID-19 SurvivorsR01HL157108 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI JULIO ALONSO CHIRINOS MEDINA, Jordana B. Cohen · 2022 to 2026
$3.9MMultidrug Metabolic Approach to Improve Exercise and Skeletal Muscle Oxidative Capacity in HFpEFR01HL157264 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ZAMANI, PAYMAN · 2021 to 2025
$3.5MInforming optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of lifeR01AG074989 · NIA · UNIVERSITY OF PENNSYLVANIA · PI BRESS, ADAM P, COHEN, JORDANA B. · 2022 to 2025
$3.3MPatient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)R01HL139837 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRESS, ADAM P, MORAN, ANDREW EDWARD · 2018 to 2021
$3.2MBlockade of calcium channels and beta adrenergic receptors for physiologic abnormalities in heart failure with preserved ejection fraction (BLOCK HFpEF)R01HL153646 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI COHEN, JORDANA B. · 2020 to 2024
$3.2MGuiding next steps for SPRINT-MIND implementation: Identifying high-benefit subgroups and comparative effects of ARB- vs. ACEI-based regimensR01AG065805 · NIA · UNIVERSITY OF UTAH · PI BRESS, ADAM P · 2020 to 2023
$2.7MHeartShare: Next-Generation Phenomics to Define Heart Failure Subtypes and Treatment Targets - Clinical CentersU01HL160277 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI JULIO ALONSO CHIRINOS MEDINA · 2021 to 2026
$1.7MUsing pharmacoepidemiology to optimize antihypertensive medication use to prevent aging-related multimorbidity: Midcareer investigator award in patient-oriented research and mentoring.K24AG080168 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Adam P Bress · 2023 to 2026
$793kStart Strong: A mixed methods study to inform initial antihypertensive prescribing and a patient-self titration intervention to improve blood pressure control, safety, and reduce cardiovascular riskK01HL175188 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI Catherine G Derington · 2025 to 2026
$339kNHLBI NIH HHS K01 HL175188NHLBI NIH HHS R01 HL139837NHLBI NIH HHS R01 HL153646NHLBI NIH HHS R01 HL155599NHLBI NIH HHS R01 HL157108NHLBI NIH HHS R01 HL157264NHLBI NIH HHS U01 HL160277NIA NIH HHS K24 AG080168NIA NIH HHS R01 AG065805NIA NIH HHS R01 AG074989NIDDK NIH HHS U24 DK060990U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) K01HL175188U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) K24AG080168
6 · The paper itselfAbstract
In this cross-sectional study of 5.8 million US adults with hypertension taking antihypertensive single-pill combination (SPC) products in the Medical Expenditure Panel Survey (2016-2022), the median out-of-pocket cost was $5.53 per SPC fill (interquartile range [IQR] $0.00-$12.70). A hypothetical small (e.g., $4/30 days) cost cap could reduce annual out-of-pocket spending by $152.9 million overall (median savings $5.35 (IQR $1.06-$12.81) per fill). A hypothetical large cost cap (e.g., $11/30 days) could reduce annual out-of-pocket spending by $61.2 million overall (median savings $2.27 (IQR $0.00-$11.28) per fill). Despite relatively low out-of-pocket costs, these spending reductions may lower patient financial burdens associated with antihypertensive SPC therapy.
Identifiers
PMID42401752
PMCPMC13591506
What OpenQuestion holds
Textmetadata
Read underepoch 390